Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | UBE2N | P61088 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6392458 | 0.91 | APP (0.64) | KDM4EKMT2AAPPALDH1A1HPGD | |
| SCHEMBL6392455 | 0.91 | APP (0.64) | KDM4EKMT2AAPPALDH1A1HPGD | |
| SCHEMBL2604928 | 0.87 | LCK (0.62) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL2092146 | 0.84 | LMNA (0.59) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL2092149 | 0.84 | LMNA (0.59) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL2604940 | 0.83 | LMNA (0.58) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL3681804 | 0.81 | LMNA (0.60) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL3672656 | 0.81 | LMNA (0.60) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL7086040 | 0.81 | CCNB2 (0.65) | LMNAKDM4EPOLBUBE2NKMT2A | |
| SCHEMBL11162008 | 0.81 | LMNA (0.56) | LMNAKDM4EPOLBUBE2NKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050452-A1 | indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents | Purdue Research Foundation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-6509344-B1 | A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-01-21 | — | — | US | disclosed |
| EP-1123099-A4 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1123099-A1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000021537-A1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2000-04-20 | — | — | WO | disclosed |